Keith A. Meister, a member of GeneDx’s Board of Directors, recently purchased 351,273 shares of the company between May 13 and May 15, 2026, at a weighted average price of $39.19 per share. This acquisition marks one of the largest transactions in Meister’s history, reflecting a significant commitment to the stock, especially given his previous trading activity, which has been infrequent. Following this purchase, Meister’s direct ownership stands at 20,129 shares, while his indirect holdings total over 5 million shares through Corvex Management and CMLS Holdings.
This transaction comes at a time when GeneDx shares have seen a dramatic decline, hitting a 52-week low of $32.21 just days prior. Despite a substantial Q1 net loss of $63.3 million, the company reported a 17% year-over-year revenue growth, indicating potential for recovery. The current price-to-sales ratio of three suggests the stock is undervalued, which may have influenced Meister’s decision to increase his stake.
For investors, Meister’s purchase signals confidence in GeneDx’s long-term prospects, especially as the company seeks to leverage its Centrellis platform for growth in the healthcare information services sector. However, the path to profitability remains uncertain, making this a critical moment for potential investors to assess the company’s recovery strategy.
Source: fool.com